Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
215 hedge funds and large institutions have $3.86B invested in Amicus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 32 closing their positions.
132% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $4.95M
17% more capital invested
Capital invested by funds: $3.3B → $3.86B (+$557M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 73
2.61% more ownership
Funds ownership: 105.31% → 107.92% (+2.6%)
5% less funds holding
Funds holding: 226 → 215 (-11)
25% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$61.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$56.4M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$46.5M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$17.6M |
| 5 |
Janus Henderson Group
London,
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$40.8M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$22.3M |
| 3 |
Millennium Management
New York
|
-$22.1M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$16.9M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$15.6M |
FOLD Hedge Fund Activity: Q2 2023 in Review
215 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2023, worth a combined $3.86B — up 17% from $3.3B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of FOLD and 24 opened new positions — a net loss of 8 holders — while 73 trimmed existing stakes and 82 added.
The largest buyer was Deutsche Bank, adding an estimated $61.1M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.
- 215 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2023, down from 226 in Q1 2023.
- Funds reported $3.86B of Amicus Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
- 24 funds opened new Amicus Therapeutics positions in Q2 2023 and 32 closed out, a net change of -8 holders.
- The largest Amicus Therapeutics buyer in Q2 2023 was Deutsche Bank, an estimated $61.1M added.
- The largest Amicus Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $40.8M sold.
Based on aggregated 13F filings for Q2 2023.